Law360, New York (July 29, 2011, 5:08 PM ET) -- Caryatid LLC accused Allergan Inc. of False Claims Act violations for marketing eye care drugs for off-label uses in kits it sold to ophthalmologists, some of whom likely filed for federal reimbursement, according to a complaint unsealed Wednesday in Washington.
U.S. District Judge Beryl A. Howell ordered the qui tam complaint unsealed after the U.S. Department of Justice said on July 18 that it would not intervene in the action.
Caryatid, which specializes in launching False Claims Act qui tam suits, alleged in January 2010 that...
Allergan Hit With Off-Label Marketing FCA Suit
To view the full article, take a free trial now.
